Autolus Therapeutics

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Autolus reports robust Q4 performance, poised for CAR T therapy success

Autolus Therapeutics demonstrated strong operational and financial performance in Q4 2022, supported by key partnerships and successful clinical data for obe-cel.
While facing challenges in competitive positioning and pricing strategy, the company has opportunities to capitalize on upcoming milestones and data releases to drive growth.
By focusing on long-term data integrity and strategic market positioning, Autolus aims to establish obe-cel as a leading therapy in the CAR T landscape.

Autolus Therapeutics reports Q1 loss, highlights CAR T progress

Autolus Therapeutics showcased progress with CAR T programs and a strong financial position
The company's focus on Obe-cel and collaborations with key partners present growth opportunities
Challenges include data disclosure queries, program potential, and partnership considerations
Opportunities lie in extending runway, expanding collaborations, and exploring new indications

Autolus Therapeutics reports strong Q2 results and eyes market expansion

Autolus Therapeutics is on track with its lead program, Obe-cel, and is making strategic moves to enhance its product portfolio and operational capabilities.
The company's financial performance remains stable, with a focus on cost management and extending its cash runway into 2025 through milestone payments.
Despite facing challenges in expense management and regulatory processes, Autolus is well-positioned to capitalize on opportunities in new indications and product development.

Autolus Therapeutics reports strong Q3 earnings and pipeline advancements

Autolus Therapeutics is making significant progress with its pipeline programs, focusing on advancing obe-cel for autoimmune diseases and presenting data at ASH.
The company's strong financial position and anticipated milestones, such as BLA filing and AUTO8 program updates, provide a solid foundation for future growth.
While facing challenges in a competitive market and logistical hurdles for pivotal trials, Autolus has opportunities to differentiate its offerings and strengthen its position in new indications.

Autolus Therapeutics reports strong financials and strategic growth opportunities

Autolus Therapeutics had a successful year financially and operationally, well positioned with a cash reserve for upcoming milestones and program expansions.
While facing regulatory challenges and cost management considerations, the company is strategically focused on expanding its therapeutic opportunities and enhancing operational efficiency.
Opportunities lie in exploring new indications, streamlining patient enrollment processes, and leveraging partnerships for broader market access and growth.

Autolus reports robust Q1 earnings, poised for strategic growth

Autolus Therapeutics demonstrated strong financial performance with increased revenue and cash reserves, positioning the company well for upcoming milestones and commercialization efforts.
While facing challenges related to accounting matters and escalating operating expenses, Autolus remains well-prepared for the launch of obe-cel and future pipeline developments.
Opportunities lie in upcoming regulatory reviews, milestone conferences, and potential treatment regimen evolution in the autoimmune space, signaling a promising outlook for Autolus.

Autolus reports robust Q3 earnings, poised for growth and innovation

Autolus Therapeutics demonstrated strong financial performance and progress in its CAR T therapy programs in Q3 2024, supported by milestone payments and a robust manufacturing facility.
While well-capitalized and positively received by physicians, the company faces challenges in cost guidance, market access strategies, and pediatric trial outcomes.
Opportunities lie in upcoming milestones, pediatric market positioning, and operational efficiency improvements, positioning Autolus for continued growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chipotle

Kinder Morgan

Wendy's

Core Laboratories Inc

Cheniere Energy Partners

CRISPR Therapeutics

DHI Group

EnLink Midstream

Hess Midstream Partners

iMedia Brands

Tyler Technologies

Welltower

Monday's futures were relatively flat, with the Nasdaq looking the best out of the group with about a 0.2% gain.

Monday's Analyst Upgrades and Downgrades: Chipotle, CRISPR, Hess Midstream, iMedia, Kinder Morgan, Wendy's and More

Autolus Therapeutics plc (NASDAQ: AUTL) has announced new data from AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed / refractory (r/r) indolent B cell lymphomas (IBCL) and r/r Adult Acute Lymphoblastic Leukemia (ALL) trials. The data were presented at the European Hematology Association Virtual Congress 2021.

Autolus Therapeutics' CAR T Cell Achieves 100% Complete Remission In Indolent B Cell Non-Hodgkin Cohort

Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence

Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress

- Data suggest that long term durability of response in acute lymphoblastic leukemia patients treated with AUTO1 is due to an enrichment of Stem Cell Memory T cells - - Data suggest that long term durability of response in acute lymphoblastic leukemia patients treated with AUTO1 is due to an enrichment of Stem Cell Memory T cells -

Autolus Therapeutics Announces an Additional Nature Publication for AUTO1

Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021

Autolus Therapeutics PLC Sponsored ADR (AUTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Autolus Therapeutics PLC Sponsored ADR (AUTL) Moves 35.5% Higher: Will This Strength Last?

The stock price of Autolus Therapeutics (NASDAQ: AUTL) increased by 35.47% today. This is why it happened.

Autolus Therapeutics (AUTL) Stock: 35.47% Increase Explanation

The company announced encouraging clinical trial data for its experimental cell therapy, AUTO1.

Why Autolus Therapeutics Stock Skyrocketed Today

AUTO1 achieves 100% complete remission rate in cohort of r/r Indolent Non- Hodgkin Lymphoma patients

Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Association Virtual Congress

Autolus Therapeutics Plc (AUTL) CEO Christian Itin on Q1 2021 Results - Earnings Call Transcript

- Conference call to be held on May 6, 2021 at 8:30 am ET/1:30 pm BST - - Conference call to be held on May 6, 2021 at 8:30 am ET/1:30 pm BST -

Autolus Therapeutics Reports First Quarter 2021 Financial Results and Operational Progress

LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received innovative licensing and access pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for AUTO4 being studied in a Phase 1 study in TRBC1 positive Peripheral T Cell Lymphoma (PTCL).

Autolus Therapeutics Receives Innovation Passport and entry into ILAP for AUTO4 for the treatment of T cell receptor constant region beta chain 1 (TRBC1) positive T cell lymphomas

LONDON, April 19, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr Martin Murphy was appointed as non-executive chairman of its Board of Directors, effective April 15, 2021.

Autolus Therapeutics announces appointment of Martin Murphy as Non-executive Chairman

LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in 1x1's at investor conferences through April 2021.

Autolus Therapeutics to Participate in Investor Conferences Through April

LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for AUTO1, the company's CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory (r/r) adult B-Acute Lymphocytic Leukemia (ALL).

Autolus Therapeutics Receives PRIME designation for AUTO1 for the treatment of adult ALL

Autolus Therapeutics' (AUTL) CEO Christian Itin on Q4 2020 Results - Earnings Call Transcript

Autolus Therapeutics PLC Sponsored ADR (AUTL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Autolus Therapeutics PLC Sponsored ADR (AUTL) Surges 6.5%: Is This an Indication of Further Gains?

LONDON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the closing of its previously announced underwritten public offering in the United States of 16,428,572 American Depositary Shares (“ADSs”) representing 16,428,572 ordinary shares, including the exercise in full by the underwriters of their option to purchase an additional 2,142,857 ADSs, at a public offering price of $7.00 per ADS. The gross proceeds to Autolus from the offering, before underwriting discounts and commissions and other offering expenses payable by Autolus, were approximately $115.0 million.

Autolus Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional ADSs

Autolus Therapeutics PLC (NASDAQ: AUTL) prices an underwritten public offering in the U.S. of 14.3 million American Depositary Shares (ADS) representing 14.3 million ordinary shares at $7 per ADS, for total gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 2.1 million ADSs.

Autolus Therapeutics Raises $100M Via Equity

LONDON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2020 financial results and operational highlights before open of U.S. markets on Thursday, March 4, 2021.

Autolus Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 4

Autolus Therapeutics PLC Sponsored ADR (AUTL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Autolus Therapeutics PLC Sponsored ADR (AUTL) Upgraded to Buy: What Does It Mean for the Stock?

• Company prioritizes AUTO1, a potentially transformational treatment for Adult Acute Lymphoblastic Leukemia (ALL), with full data from the AUTO1-AL1 study expected in 2022 •  Company intends to partner AUTO3, ahead of progressing into the next phase of development •  Company adjusting its workforce and infrastructure footprint to align with AUTO1 prioritization

Autolus Therapeutics provides business outlook for 2021 & 2022

LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021.

Autolus Therapeutics to participate in Investor Conferences through January

AUTO3 continues to show a differentiated product profile supporting outpatient administration

Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting

Updated data from the ALLCAR study suggests AUTO1's potential for transformational activity in adult patients with r/r ALL

Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting

News for Autolus Therapeutics Stock (AUTL)